About: Cambridge Antibody Technology Group Plc   Goto Sponge  NotDistinct  Permalink

An Entity of Type : owl:Thing, within Data Space : platform.yourdatastories.eu:8890 associated with source document(s)

Cambridge Antibody Technology (officially Cambridge Antibody Technology Group Plc, informally CAT) was a biotechnology company headquartered in Cambridge, England, United Kingdom. Its core focus was on antibody therapeutics, primarily using phage display and ribosome display technology.Technology developed by CAT was used to create adalimumab, the first fully human antibody blockbuster drug.

AttributesValues
rdfs:comment
  • Cambridge Antibody Technology (officially Cambridge Antibody Technology Group Plc, informally CAT) was a biotechnology company headquartered in Cambridge, England, United Kingdom. Its core focus was on antibody therapeutics, primarily using phage display and ribosome display technology.Technology developed by CAT was used to create adalimumab, the first fully human antibody blockbuster drug.
foaf:name
  • Cambridge Antibody Technology Group Plc
foaf:depiction
  • External Image
assets ($)
  • 215.98
equity ($)
  • 180.97
extinction year
fate
  • Acquired byAstraZenecain 2006; combined withMedImmunein 2007
foundation place
founded by
founding year
internationally
key person
location
net income ($)
  • 25.25
number of employees
operating income ($)
  • 147.25
owner
owning company
product
revenue ($)
  • 172.5
service
successor
thumbnail
type
is known for of
Faceted Search & Find service v1.13.91 as of Nov 14 2017


Alternative Linked Data Documents: ODE     Content Formats:       RDF       ODATA       Microdata      About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data]
OpenLink Virtuoso version 07.20.3212 as of Mar 29 2016, on Linux (x86_64-unknown-linux-gnu), Single-Server Edition (68 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software